Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Cybin Inc. < Previous 1 2 3 4 5 6 Next > Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation August 27, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder August 13, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights August 08, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference August 07, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights June 26, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference June 19, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development June 11, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024 May 29, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase May 14, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones May 06, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Participate at the 27th Annual Milken Institute Global Conference April 25, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry April 18, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder April 16, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference April 10, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas March 18, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder March 15, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design March 14, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder March 13, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003 March 12, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Present at the TD Cowen 44th Annual Health Care Conference February 27, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Reports Third Quarter Financial Results and Recent Business Highlights February 14, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program February 07, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder January 23, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028 January 08, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs January 04, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program December 06, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results December 05, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses November 30, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City November 20, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023 November 16, 2023 From Cybin Inc. Via Business Wire Tickers CYBN < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.